The work was carried out by Na-Yeong Heo, Mi-Jung Kang, and Yeon-Gu Kim at the Biotherapeutics Translational Research Center of the Korea Research Institute of Bioscience and Biotechnology, with Heo and Kim also affiliated with the KRIBB School of Biotechnology at the Korea University of Science and Technology. Their central insight addresses a long-standing frustration in industrial biomanufacturing: codon optimization has become a routine strategy for boosting recombinant protein expression in mammalian systems, yet improvements in codon-usage-based computational metrics do not always translate into enhanced production performance. In other words, an algorithm that scores a gene as well adapted to a host cell’s codon preferences may still deliver a disappointing yield at the bioreactor scale.

To understand why this matters, it helps to consider the biology of the genetic code. The code is degenerate: most amino acids are specified by multiple three-letter codons, and different organisms favor different synonyms. Since the early days of recombinant DNA technology, scientists have exploited this redundancy, rewriting therapeutic genes to match the codon preferences of the production host in the hope of speeding translation. But codon usage influences far more than translation speed. Synonymous changes can affect mRNA secondary structure, mRNA stability and abundance, the kinetics of translation initiation, co-translational folding of the nascent protein, and even the recruitment of regulatory RNA-binding proteins. Because these effects are intertwined and context-dependent, no single computational metric captures the full picture. That is precisely the gap the Korean team set out to close with an empirical, cell-based approach.

The production host at the heart of the study is the Chinese hamster ovary cell, or CHO cell, the workhorse of the biopharmaceutical industry. CHO cells are used to manufacture a large share of the world’s therapeutic proteins because they can perform complex post-translational modifications—particularly N-linked glycosylation—that are essential for the safety and efficacy of many biologics. Etanercept is a prime example: it is a fusion protein linking the extracellular domain of the human p75 tumor necrosis factor receptor to the Fc portion of human immunoglobulin G1, and it requires proper N-terminal processing and N-linked glycosylation to function correctly. Any engineering strategy that raises yield but compromises these quality attributes would be unacceptable, which is why the researchers built quality assessment directly into their screening pipeline.

Methodologically, the study focused on the 5′ coding region of the etanercept gene, the stretch of DNA immediately downstream of the start codon. This region is known to exert outsized influence on translation initiation and early elongation, making it a strategic target for synonymous redesign. The team constructed a library of synonymous codon variants concentrated in this 5′ region and introduced the variants into Flp-In CHO cells, a specialized line engineered for Flp/FRT-mediated site-specific integration. This system allows an incoming gene to recombine at a defined genomic locus, ensuring that every variant in the library is inserted at the same chromosomal address. The importance of this design choice cannot be overstated: in conventional random integration, each cell clone carries the transgene at a different genomic position, and the resulting position effects—local chromatin environment, enhancer proximity, epigenetic silencing—often swamp any true sequence-dependent differences in expression. By pinning every variant to the same locus, the researchers eliminated this confounding variable and made a fair, apples-to-apples comparison of synonymous sequences possible.

With the library in place, the next challenge was finding the rare high performers among many mediocre ones. The researchers employed a fluorescence-activated cell sorting-based antibody detection assay to enrich variants that produced more etanercept on their cell surfaces or in their secreted product. FACS allows millions of cells to be sorted individually at high speed based on a fluorescent signal proportional to protein production, effectively turning the entire cell population into a searchable library. After enrichment, the top candidates were evaluated under stable gene expression conditions, the gold standard for assessing whether a production advantage is durable rather than a transient artifact of transfection or selection. Three variants emerged from this process as clear winners: ETN-Syn-4, ETN-Syn-14, and ETN-Syn-25.

The productivity gains were striking. Compared with cells carrying the native etanercept sequence, the three top variants yielded 2.08-fold, 2.75-fold, and 2.08-fold higher specific protein productivity, a parameter denoted qp that measures the amount of product generated per cell over time. A nearly threefold improvement in specific productivity is a meaningful advance in an industry where even incremental gains in titer or cell-specific productivity can translate into substantial cost savings across thousands of liters of fermentation capacity. Perhaps the most intriguing finding, however, was what did not change dramatically: the mRNA abundance of the three top-producing variants showed only modest differences from the native sequence. This suggests that the productivity boost was not primarily driven by increased transcription or mRNA stability, pointing instead toward translational mechanisms—more efficient initiation, smoother ribosome transit, or improved co-translational folding—that allow the same amount of messenger RNA to yield more finished protein.

The selected variants also displayed distinct sequence characteristics, differing from one another and from the native gene in their codon-usage profiles. This heterogeneity among the winners is itself informative: it implies there is no single optimal codon recipe, but rather multiple synonymous solutions that converge on high productivity through different combinations of sequence features. Such diversity complicates purely rational design but validates the screening approach, which can discover effective variants that no current algorithm would necessarily rank at the top. The findings reinforce a growing consensus in the field that synonymous codon choice is a rich, underexploited design dimension for bioprocess engineering, one whose effects are best mapped empirically in the actual production host.

Critical to any real-world application is the question of product quality, and here the results were reassuring. The researchers compared etanercept derived from the synonymous variants with native-sequence etanercept across several key quality attributes: N-terminal processing, N-linked glycosylation, size heterogeneity, and binding activity. In each case, the variant-derived protein was comparable to the native product. This means the codon changes boosted quantity without altering the molecular identity or functional integrity of the drug—a crucial distinction, because regulatory agencies demand thorough characterization of glycosylation patterns and other critical quality attributes for every biologic, and even subtle shifts can trigger lengthy revalidation. A silent mutation strategy that preserves product quality while raising yield is therefore far more attractive than approaches that trade quality for quantity.

The broader implications extend well beyond etanercept. The screening framework established in this study—combining site-specific integration, focused synonymous libraries, FACS-based enrichment, and rigorous quality control—offers a generalizable template for optimizing any therapeutic protein produced in CHO cells. As the biopharmaceutical industry faces relentless pressure to reduce manufacturing costs and expand access to biologics, tools that squeeze more product from each cell without new cell lines or process overhauls are increasingly valuable. The work, supported by the National Research Foundation of Korea through the KRIBB Research Initiative Program and by Korea’s Ministry of Trade, Industry and Energy, signals a shift in how codon optimization is practiced: away from purely in silico design and toward empirical, cell-based selection that lets the biology itself reveal which silent spellings speak loudest. For a field built on the assumption that the genetic code’s redundancy is just that—redundant—this study is a reminder that synonymous DNA is anything but silent when it comes to making medicines.

Subject of Research: Empirical screening of synonymous codon variants to enhance therapeutic protein production in Chinese hamster ovary cells

Article Title: Synonymous codon variants identified by in vitro screening enhance etanercept production in CHO cells

Article References: Heo, N.-Y., Kang, M.-J., & Kim, Y.-G. (2026). Synonymous codon variants identified by in vitro screening enhance etanercept production in CHO cells. Applied Microbiology and Biotechnology. https://doi.org/10.1007/s00253-026-14057-9

Image Credits: AI Generated

DOI: 10.1007/s00253-026-14057-9

Keywords: codon optimization, synonymous codon variants, CHO cells, etanercept, Fc-fusion protein, recombinant protein expression, Flp-In site-specific integration, FACS screening, specific productivity, N-linked glycosylation, bioprocess engineering, therapeutic glycoprotein

To appreciate why this matters, it helps to understand how the glutamine synthetase system has worked for decades. Chinese hamster ovary cells, or CHO cells, are the workhorses of the biotechnology industry, producing the majority of recombinant therapeutic proteins on the market, from monoclonal antibodies to enzyme replacement therapies. When researchers want a CHO cell line to make a therapeutic protein, they typically link the gene for that protein to the gene for glutamine synthetase, an enzyme that allows cells to synthesize glutamine, an amino acid essential for growth. When the cells are grown in medium lacking glutamine and containing methionine sulfoximine, an inhibitor of glutamine synthetase, only cells that produce enough of the enzyme survive. The logic is straightforward: cells that have integrated more copies of the construct, or that express it more strongly, make more glutamine synthetase and therefore grow better under selection. Over time, this enriches the population for high-producing clones.

But the system has a well-known weakness, and it lies in the intrinsic biochemistry of glutamine synthetase itself. The protein is remarkably stable inside the cell, persisting long after it is made. That stability means that even cells with modest expression of the construct accumulate enough enzyme to survive selection. In practical terms, the selection stringency is low: the survival bar is easy to clear, and cells with suboptimal productivity slip through alongside the rare high performers. Traditional workarounds involve escalating concentrations of methionine sulfoximine or laborious rounds of gene amplification and clone screening, both of which add months to cell line development and introduce regulatory and manufacturing complexities. Methionine sulfoximine, after all, is a chemical inhibitor that must be rigorously controlled and eventually removed from the production process, and amplified gene copies can be unstable over long culture periods.

The Inha team approached the problem from an angle that has become increasingly fashionable in cell engineering: proteostasis, the tightly regulated balance between protein synthesis and protein degradation. Rather than trying to control how much glutamine synthetase mRNA is transcribed or translated, they attacked the protein itself, engineering variants that carry modular degrons, short peptide sequences that tag a protein for destruction by the cell’s own degradation machinery. By fusing these degrons to glutamine synthetase, the researchers created what they call destabilized GS, or dGS, variants that are actively and continuously broken down inside the cell. A cell can only maintain sufficient glutamine synthetase activity if it produces the protein at a very high rate, which in turn requires high expression of the linked construct. The degradation tag effectively raises the survival bar, making selection far more stringent without changing the selection conditions at all.

The researchers tested this concept in CHO cells engineered to express either a reporter protein or Etanercept, a fusion protein that combines an antibody fragment with a tumor necrosis factor receptor and is used to treat autoimmune conditions such as rheumatoid arthritis. When the standard, stable glutamine synthetase was used as the selection marker, the resulting cell pools showed the familiar pattern: a broad distribution of productivity, with many mediocre producers surviving selection. When the destabilized GS variants were used instead, the picture changed markedly. The dGS-selected pools were selectively enriched for cells with markedly enhanced productivity, demonstrating that accelerating protein turnover translates directly into stronger selection pressure. The effect worked across both the reporter system and the commercially relevant Etanercept construct, suggesting the strategy is general rather than product-specific.

Molecular analysis of the enriched pools revealed something particularly interesting about where the productivity gains came from. A common assumption in cell line development is that higher productivity comes from gene amplification, meaning the cells have acquired more copies of the therapeutic gene, often through selection regimes designed to force amplification. But when the team examined the dGS pools, they found that the improvements were driven primarily by increased per-copy mRNA abundance rather than by an increase in gene copy number. In other words, the cells that survived the stringent selection were not those with the most genes, but those that made the most messenger RNA from each copy they had. This distinction is significant for manufacturing, because per-copy expression efficiency can be more stable across long production runs than amplified gene arrays, which are prone to silencing or loss over time.

The performance numbers underscore the practical potential of the approach. The top-performing dGS pool achieved an Etanercept titer of 870 milligrams per liter in shake-flask batch culture, a respectable figure for a non-optimized, drug-free system that did not rely on extensive gene amplification. Equally important, the pool maintained stable production over 80 days of continuous passaging, indicating that the high-producing phenotype was not a transient artifact of selection but a durable property of the enriched cell population. Stability over weeks of culture is a critical requirement for commercial manufacturing, where a production campaign can run for many weeks and any decline in titer translates directly into lost product and higher costs. The fact that these results were obtained without chemical selection agents or amplification regimes suggests the method could simplify both the development timeline and the regulatory dossier for new biologic drugs.

The broader significance of the study lies in its demonstration that proteostasis engineering, the deliberate manipulation of protein degradation rates, can serve as a design tool for selection systems, not just as a way to study protein turnover. By choosing or tuning a degron, researchers can in principle dial in exactly how much of a survival protein a cell must produce to stay alive, converting a binary drug-based selection into a graded, high-stringency filter that favors the best producers. Because the strategy operates at the level of protein stability rather than transcription or translation, it is conceptually orthogonal to existing optimization approaches and could be combined with them. The authors suggest that this capability has the potential to accelerate cell line development and reduce manufacturing complexity in biopharmaceutical production, two goals that the industry pursues relentlessly given the enormous cost and time pressures of bringing a biologic to market.

There are, of course, questions that future work will need to address before degradable selection markers become standard practice in industrial cell line development. The study was conducted at shake-flask scale, and performance in the stirred-tank bioreactors used for commercial manufacturing will need to be confirmed. The long-term behavior of degron-tagged proteins under the metabolic stresses of large-scale culture, and the interaction of accelerated protein degradation with the cellular burden of producing a therapeutic protein at high levels, remain areas for further investigation. Nevertheless, the core result stands as a striking proof of concept: by making an essential enzyme deliberately fragile, the researchers turned the cell’s own protein quality control system into a powerful engine for finding its best producers. In an industry where every percentage point of titer improvement carries real economic weight, teaching selection systems to exploit proteostasis may prove to be one of the more consequential ideas to emerge from cell line engineering in recent years.

Subject of Research: Proteostasis engineering of glutamine synthetase for stringent, drug-free selection of high-producing Chinese hamster ovary cell lines

Article Title: Proteostasis engineering of glutamine synthetase for stringent, drug-free selection in Chinese hamster ovary cells

Article References: Kim, H., Park, J. U., Ha, J., & Baik, J. Y. (2026). Proteostasis engineering of glutamine synthetase for stringent, drug-free selection in Chinese hamster ovary cells. Applied Microbiology and Biotechnology. https://doi.org/10.1007/s00253-026-14015-5

Image Credits: AI Generated

DOI: 10.1007/s00253-026-14015-5

Keywords: CHO cells, glutamine synthetase, proteostasis, degrons, protein degradation, selection stringency, cell line development, biopharmaceutical manufacturing, Etanercept, per-copy mRNA abundance, drug-free selection, protein stability